N-[(2-methoxyphenyl)methyl]-3-(2H-triazol-4-yl)aniline

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[(2-methoxyphenyl)methyl]-3-(2H-triazol-4-yl)aniline
• 化学式: C₁₆H₁₆N₄O
• 分子量: 280.32
• InChiKey: WRCRDYOWYPJRNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  62.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] COMPOUNDS AND METHODS<br/>[FR] COMPOSES ET PROCEDES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2003031434A1

  公开（公告）日：2003-04-17

  Disclosed are compounds of formula (I) wherein the formula variables are as defined herein. The compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase. Also disclosed is the use of such compounds in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.

  本发明揭示了式(I)的化合物，其中式变量如本文所定义。本发明的化合物是非肽类，可逆抑制剂，可抑制2型蛋氨酸氨肽酶。本发明还揭示了这些化合物在治疗由血管生成介导的疾病方面的用途，如癌症、血管瘤、增生性视网膜病变、类风湿性关节炎、动脉粥样硬化性新生血管形成、牛皮癣、眼部新生血管形成和肥胖症。
• Compounds and methods
  申请人：——

  公开号：US20040192914A1

  公开（公告）日：2004-09-30

  Disclosed are compounds of the formula: 1 wherein the formula variables are as defined herein. The compounds of this invention are non-peptide, reversible inhibitors of type 2 methionine aminopeptidase. Also disclosed is the use of such compounds in treating conditions mediated by angiogenesis, such as cancer, haemangioma, proliferative retinopathy, rheumatoid arthritis, atherosclerotic neovascularization, psoriasis, ocular neovascularization and obesity.

  本发明揭示了式1的化合物：其中式中的变量在此定义。本发明的化合物是非肽类、可逆抑制剂2型甲硫氨酰肽酶。本发明还揭示了这些化合物在治疗通过血管生成介导的疾病中的应用，例如癌症、血管瘤、增生性视网膜病变、类风湿性关节炎、动脉粥样硬化性新生血管形成、牛皮癣、眼部新生血管形成和肥胖症。
• Piperidine and piperazine derivatives possessing affinity at 5ht-1 type receptors
  申请人：Flynn F. Sean

  公开号：US20050176724A1

  公开（公告）日：2005-08-11

  Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein A is optionally substituted phenyl, indolyl, quinolinyl, quinazolinyl, indazolyl or isoquinolinyl; X is carbon, Y is CH and ═ is a double bond; or X is CH, Y is CH 2 or oxygen and ═ is a single bond; or X is nitrogen, Y is CH 2 and ═ is a single bond; R 1 is halogen, cyano, nitro, C 1-6 alkyl, haloC 1-6 alkyl, C 1-6 alkoxy, C 3-7 heterocyclylC 1-6 alkyl, C 3-7 heterocyclyl C 1-6 alkoxy; a is 0, 1, 2, 3 or 4; R2 is either: halogen, —CN, an optionally substituted C 3-7 cycloalkyl, an optionally substituted aryl or an optionally substituted C-linked 3-7 membered heterocyclic group; or a group -(Z)b-B wherein: (i) Z is oxygen, CH 2 , C═O, SO 2 or C═N—OR3 wherein R3 is hydrogen or C 1-6 alkyl; b is 1, 2, or 3; and B is hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkoxy or NR4R5 wherein R4 and R5 are independently hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, C 1-6 alkanoyl, fluoroC 1-6 alkanoyl, C 1-6 alkylsulfonyl, fluoroC 1-6 alkylsulfonyl, carbamoyl or C 1-6 alkylcarbamoyl, or R4 and R5, together with the nitrogen atom to which they are attached, form part of an optionally substituted 3 to 7 membered heterocyclic group; or (ii) Z is oxygen, CH or CH 2 , b is 1, and B forms the rest of an aryl or a C 3-7 heterocyclic group fused to the phenyl ring; excluding 1-[2-[2-(phenylmethyl)phenoxy]ethyl]-4-[(2,3,4-trimethoxyphenyl)methyl]-piperazine and pharmaceutically acceptable salts thereof, and N-[4-[2-[4-[(3,4-dimethoxyphenyl)methyl]-1-piperazinyl]ethoxy]phenyl]-ethanesulfonamide and pharmaceutically acceptable salts thereof. Methods of preparing the compounds and uses of the compounds in therapy, in particular for CNS disorders such as depression and anxiety, are also disclosed.

  本文披露了公式(I)的化合物及其药学上可接受的盐：其中A是可选取代的苯基、吲哚基、喹啉基、喹唑啉基、吲唑基或异喹啉基；X为碳，Y为CH，═为双键；或X为CH，Y为CH2或氧，═为单键；或X为氮，Y为 ，═为单键；R1为卤素、氰基、硝基、C1-6烷基、卤代C1-6烷基、C1-6烷氧基、C3-7杂环烷基C1-6烷基、C3-7杂环烷基C1-6烷氧基；a为0、1、2、3或4；R2为：卤素、-CN、可选取代的C3-7环烷基、可选取代的芳基或可选取代的C-连接的3-7环成员杂环基；或一个-(Z)b-B基团，其中：(i)Z为氧、 、C═O、SO2或C═N—OR3，其中R3为氢或C1-6烷基；b为1、2或3；B为氢、C1-6烷基、C3-7环烷基、C1-6烷氧基或NR4R5，其中R4和R5独立地为氢、C1-6烷基、C3-7环烷基、C1-6烷酰基、氟代C1-6烷酰基、C1-6烷基磺酰基、氟代C1-6烷基磺酰基、氨基或C1-6烷基氨基；或R4和R5与它们所连接的氮原子一起构成可选取代的3到7环成员杂环基的一部分；或(ii)Z为氧、CH或 ，b为1，B为连接到苯环或C3-7杂环基的其余部分的芳基或C3-7杂环基；不包括1-[2-[2-(苯甲基)苯氧基]乙基]-4-[(2,3,4-三甲氧基苯基)甲基]-哌嗪和其药学上可接受的盐，以及N-[4-[2-[4-[(3,4-二甲氧基苯基)甲基]-1-哌嗪基]乙氧基]苯基]-乙烷磺酰胺和其药学上可接受的盐。本文还披露了制备这些化合物的方法以及这些化合物在治疗中的应用，特别是在中枢神经系统疾病如抑郁症和焦虑症中的应用。
• COMPOUNDS AND METHODS
  申请人：SmithKline Beecham Corporation

  公开号：EP1434772A1

  公开（公告）日：2004-07-07
• EP1434772A4
  申请人：——

  公开号：EP1434772A4

  公开（公告）日：2005-05-04